Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Orion Corporation, Orion Pharma
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent
Asthma diagnosis for at least 6 months
Prebronchodilator FEV1 45-90% of the predicted value
Demonstration of reversible airway obstruction
Stable asthma on the same regular treatment for at least 4 weeks before the study
Non-smoker for at least 6 months before the study
You may not be if
Respiratory infection within 4 weeks before the study
Smoking history of more than 10 pack-years
Other severe chronic respiratory disease than asthma
Concurrent illness that would interfere with the interpretation of the study results or constitute a health risk for the patient if he/she takes part in the study
Corrected QT interval \> 450 ms in males or \> 470 ms in females
Abnormal serum potassium value or other clinically significant laboratory finding
Systolic blood pressure over 180 mmHg and/or diastolic blood pressure over 100 mmHg
Treatment with a long-acting β2-agonist, a xanthine-derivative, a β-blocker or with a corticosteroid (other than inhaled) within 4 weeks before the study
Use of drugs that prolong QT-interval
Women who are pregnant, breast-feeding or without reliable contraception
